"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A3,WO 2024/030536 A3,088-089-661-966-74X,2024-03-07,2024,US US2023/029384,2023-08-03,"US 63/3/094,911",2022-08-03,MEASURING INTRACRANIAL PRESSURE USING A CEREBROSPINAL FLUID SHUNT DEVICE,"Intracranial pressure is determined for a patient that has a cerebrospinal fluid (CSF) shunt. Intracranial pressure information is required to manage the care of patients with CSF shunts. Disclosed is a method by which information about intracranial pressures can be obtained using noninvasive measurements, such as an MRI scan. The method provides advantages of avoiding expensive, invasive surgeries and improves clinical patient outcomes due to the ability to monitor intracranial pressure and shunt function, and appropriately titrate patient-specific valve settings.",CHILDREN'S HOSPITAL LOS ANGELES,"BORZAGE, Matthew;;CHIARELLI, Peter;;HA, Joseph Hyunjong",,https://lens.org/088-089-661-966-74X,Search Report,yes,0,0,1,1,0,,A61B5/03;;A61M27/00;;A61M1/00,,0,0,,,,UNKNOWN
2,WO,A2,WO 2024/030536 A2,058-558-717-177-880,2024-02-08,2024,US 2023/0029384 W,2023-08-03,US 202263394911 P,2022-08-03,MEASURING INTRACRANIAL PRESSURE USING A CEREBROSPINAL FLUID SHUNT DEVICE,"Intracranial pressure is determined for a patient that has a cerebrospinal fluid (CSF) shunt. Intracranial pressure information is required to manage the care of patients with CSF shunts. Disclosed is a method by which information about intracranial pressures can be obtained using noninvasive measurements, such as an MRI scan. The method provides advantages of avoiding expensive, invasive surgeries and improves clinical patient outcomes due to the ability to monitor intracranial pressure and shunt function, and appropriately titrate patient-specific valve settings.",LOS ANGELES CHILDRENS HOSPITAL,BORZAGE MATTHEW;;CHIARELLI PETER;;HA JOSEPH HYUNJONG,,https://lens.org/058-558-717-177-880,Patent Application,yes,0,0,1,1,0,G01S7/20;;G06T5/60,G06T5/60;;G01S7/20,,0,0,,,,PENDING
3,US,A1,US 2023/0050896 A1,189-831-900-585-078,2023-02-16,2023,US 202217879171 A,2022-08-02,US 202217879171 A;;US 202163203918 P,2021-08-04,MARINE-BASED GELATIN POWDERS AND METHODS OF MAKING,Provided are gelatin powders and gels derived from marine sources of collagen such as jellyfish. Also provided are methods for producing marine-derived gelatin powders. The marine-derived collagen source is hydrolyzed then dialyzed to at least partially demineralize the marine-derived collagen source.,UNIV GEORGIA,MIS SOLVAL KEVIN ESTUARDO;;CHIARELLI PETER GEORGE;;CHEN JINRU,UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC (2022-08-03),https://lens.org/189-831-900-585-078,Patent Application,yes,0,0,1,1,0,C08L89/06;;C08H1/06;;C08J2489/04;;C08L89/06;;C08J3/12,C08H1/06;;C08J3/12;;C08L89/06,,0,0,,,,PENDING
4,WO,A1,WO 2023/122181 A1,006-205-432-886-229,2023-06-29,2023,US 2022/0053668 W,2022-12-21,US 202163293597 P,2021-12-23,IRON OXIDE NANOPARTICLE-MEDIATED RADIATION DELIVERY FOR TARGETED CANCER TREATMENT,Method for nanoparticle-mediated deposition of radiation (NMDR) and targeted radiation therapies using a biodegradable and bioabsorbable iron oxide nanoparticle with a biocompatible coating that is effective to overcome various extra- and intra-cellular barriers and selectively accumulate in solid and metastatic tumors to improve the energy transfer of conventional radiotherapy,UNIV WASHINGTON,ZHANG MIQIN;;CHIARELLI PETER;;REVIA RICHARD;;STEPHEN ZACHARY;;KIEVIT FORREST;;WANG KUI;;ELLENBOGEN RICHARD,,https://lens.org/006-205-432-886-229,Patent Application,yes,5,0,1,1,0,B82Y5/00;;A61K33/26;;A61K41/0038;;A61P35/00;;H01F1/0054;;C01G49/06,B82Y30/00;;A61K33/26;;B82Y5/00;;B82Y40/00;;C01G49/02,,0,0,,,,PENDING
5,WO,A1,WO 2022/076545 A1,106-676-285-768-228,2022-04-14,2022,US 2021/0053753 W,2021-10-06,US 202063089403 P,2020-10-08,IRON OXIDE NANOPARTICLE FOR SUPPRESSING DRUG-RESISTANT GENE FOR THE TREATMENT OF GLIOBLASTOMA,"A nanoparticle for targeted siRNA delivery comprising an iron oxide core and a chitosan-polyethylene glycol-polyethylenimine copolymer coating surrounding the core, chlorotoxin covalently coupled to the coating, and an siRNA reversibly associated to the coating by non-covalent interaction. Methods for making the nanoparticle and methods for using the nanoparticle to suppress the expression of O 6 -methylguanine-DNA methyltransferase (MGMT), treating brain cancer, and killing cancer stem cells.",UNIV WASHINGTON,ZHANG MIQIN;;ELLENBOGEN RICHARD;;WANG KUI;;KIEVIT FORREST;;SILBER JOHN;;STEPHEN ZACHARY;;CHIARELLI PETER,,https://lens.org/106-676-285-768-228,Patent Application,yes,2,1,2,2,2,A61K47/62;;A61K47/6923;;A61K47/6925;;A61K47/62;;A61K47/6923;;A61K47/6925;;A61P35/00;;A61K47/34;;C12N15/1137,A61K9/16;;A61K9/14,,0,0,,,,PENDING
6,US,A1,US 2004/0086649 A1,105-425-037-617-735,2004-05-06,2004,US 61851703 A,2003-07-11,US 61851703 A;;US 39567802 P,2002-07-12,Fabrication of multilayered thin films via spin-assembly,"
   An process of forming multilayer thin film heterostructures is disclosed and includes applying a solution including a first water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species onto a substrate to form a first coating layer on the substrate, drying the first coating layer on the substrate, applying a solution including a second water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species onto the substrate having the first coating layer to form a second coating layer on the first coating layer wherein the second water-soluble polymer is of a different material than the first water-soluble polymer, and drying the second coating layer on the first coating layer so as to form a bilayer structure on the substrate. Optionally, one or more additional applying and drying sequences can be repeated with a water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species, so that a predetermined plurality of layers are built up upon the substrate. 
",CHIARELLI PETER A.;;ROBINSON JEANNE M.;;CASSON JOANNA L.;;JOHAL MALKIAT S.;;WANG HSING-LIN,CHIARELLI PETER A;;ROBINSON JEANNE M;;CASSON JOANNA L;;JOHAL MALKIAT S;;WANG HSING-LIN,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2003-11-25);;LOS ALAMOS NATIONAL SECURITY LLC (2006-04-24),https://lens.org/105-425-037-617-735,Patent Application,yes,11,9,2,2,0,B05D1/005;;B05D1/185;;B05D7/52;;B05D7/56;;B82Y30/00;;B82Y40/00;;B82Y30/00;;B05D7/52;;B05D7/56;;B82Y40/00;;B05D1/185;;B05D1/005,B05D1/00;;B05D1/18;;B05D7/00,427/384;;X42724;;427/163.2;;385/145,0,0,,,,EXPIRED
7,US,B2,US 7179679 B2,161-521-142-900-752,2007-02-20,2007,US 61851703 A,2003-07-11,US 61851703 A;;US 39567802 P,2002-07-12,Fabrication of multilayered thin films via spin-assembly,"An process of forming multilayer thin film heterostructures is disclosed and includes applying a solution including a first water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species onto a substrate to form a first coating layer on the substrate, drying the first coating layer on the substrate, applying a solution including a second water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species onto the substrate having the first coating layer to form a second coating layer on the first coating layer wherein the second water-soluble polymer is of a different material than the first water-soluble polymer, and drying the second coating layer on the first coating layer so as to form a bilayer structure on the substrate. Optionally, one or more additional applying and drying sequences can be repeated with a water-soluble polymer from the group of polyanionic species, polycationic species and uncharged polymer species, so that a predetermined plurality of layers are built up upon the substrate.",UNIV CALIFORNIA,CHIARELLI PETER A;;ROBINSON JEANNE M;;CASSON JOANNA L;;JOHAL MALKIAT S;;WANG HSING-LIN,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2003-11-25);;LOS ALAMOS NATIONAL SECURITY LLC (2006-04-24),https://lens.org/161-521-142-900-752,Granted Patent,yes,12,0,2,2,0,B05D1/005;;B05D1/185;;B05D7/52;;B05D7/56;;B82Y30/00;;B82Y40/00;;B82Y30/00;;B05D7/52;;B05D7/56;;B82Y40/00;;B05D1/185;;B05D1/005,H01L51/56;;B05D1/00;;B05D1/18;;B05D7/00,438/99;;427/97.5;;427/384;;385/145,5,5,072-516-173-959-797;;032-044-884-832-983;;077-012-373-461-128;;139-453-236-379-292;;005-554-695-987-717,10.1021/ma981927a;;10.1021/la034788l;;10.1021/la011333s;;10.1002/1521-4095(200107)13:14<1076::aid-adma1076>3.0.co;2-m;;10.1126/science.277.5330.1232,"Dubas et al., ""Factors Controlling the Growth of Polyelectrolyte Multilayers,"" Macromolecules, vol. 32, pp. 8153-8160, 1999.;;Johal et al., ""Polyelectrolyte Trilayer Combinations Using Spin-Assembly and Ionic Self-Assembly,"" Langmuir, vol. 19, pp. 8876-8881, 2003.;;Chiarelli et al., ""Polyelectrylyte Spin-Assembly,"" Langmuir, vol. 18, pp. 168-173, 2002.;;Cho et al., ""Fabrication of Highly Ordered Multilayer Films Using a Spin Self-Assembly Method,"" Adv. Mater, vol. 13, No. 14, pp. 1076-1078, 2001.;;Decher, ""Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites,"" Science, vol. 277, pp. 1232-1237, 1997.",EXPIRED
8,US,A1,US 2023/0405145 A1,152-972-247-405-236,2023-12-21,2023,US 202118248139 A,2021-10-06,US 202118248139 A;;US 202063089403 P;;US 2021/0053753 W,2020-10-08,IRON OXIDE NANOPARTICLE FOR SUPPRESSING DRUG-RESISTANT GENE FOR THE TREATMENT OF GLIOBLASTOMA,"A nanoparticle for targeted siRNA delivery comprising an iron oxide core and a chitosan-polyethylene glycol-polyethylenimine copolymer coating surrounding the core, chlorotoxin covalently coupled to the coating, and an siRNA reversibly associated to the coating by non-covalent interaction. Methods for making the nanoparticle and methods for using the nanoparticle to suppress the expression of O 6 -methylguanine-DNA methyltransferase (MGMT), treating brain cancer, and killing cancer stem cells.",UNIV WASHINGTON,ZHANG MIQIN;;ELLENBOGEN RICHARD G;;WANG KUI;;KIEVIT FORREST M;;SILBER JOHN R;;STEPHEN ZACHARY;;CHIARELLI PETER A,UNIVERSITY OF WASHINGTON (2021-10-06),https://lens.org/152-972-247-405-236,Patent Application,yes,0,0,2,2,2,A61K47/62;;A61K47/6923;;A61K47/6925;;A61K47/62;;A61K47/6923;;A61K47/6925;;A61P35/00;;A61K47/34;;C12N15/1137,A61K47/69;;A61K47/34;;A61K47/62;;A61P35/00;;C12N15/113,,0,0,,,,PENDING
9,US,A1,US 2018/0289736 A1,053-701-856-956-806,2018-10-11,2018,US 201615766314 A,2016-10-06,US 201615766314 A;;US 201562237915 P;;US 2016/0055809 W,2015-10-06,OXYGEN REACTIVE POLYMERS FOR TREATMENT OF TRAUMATIC BRAIN INJURY,"Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.",UNIV WASHINGTON,STAYTON PATRICK S;;YPMA MENKO R;;CHIARELLI PETER A;;PARK JOSHUA SANG HUN;;ELLENBOGEN RICHARD G;;XU JULIA MENGYUN;;MOURAD PIERRE D;;LEE DONGHOON;;CONVERTINE ANTHONY;;KIEVIT FORREST M,UNIVERSITY OF WASHINGTON (2018-11-01),https://lens.org/053-701-856-956-806,Patent Application,yes,0,0,4,4,0,A61K47/30;;A61K9/14;;A61P25/28;;A61K31/765;;A61K31/795;;A61K47/30;;A61K9/14;;A61P25/28;;A61K9/0019;;A61K9/51;;A61K31/765;;A61K31/795,A61K31/765;;A61K9/00;;A61K9/51;;A61K31/795;;A61P25/28,,0,0,,,,ACTIVE
10,US,B2,US 11065272 B2,027-745-356-809-270,2021-07-20,2021,US 201615766314 A,2016-10-06,US 201615766314 A;;US 201562237915 P;;US 2016/0055809 W,2015-10-06,Oxygen reactive polymers for treatment of traumatic brain injury,"Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.",UNIV WASHINGTON,STAYTON PATRICK S;;YPMA MENKO P;;CHIARELLI PETER A;;PARK JOSHUA SANG HUN;;ELLENBOGEN RICHARD G;;XU JULIA MENGYUN;;MOURAD PIERRE D;;LEE DONGHOON;;CONVERTINE ANTHONY;;KIEVIT FORREST M,UNIVERSITY OF WASHINGTON (2018-11-01),https://lens.org/027-745-356-809-270,Granted Patent,yes,7,0,4,4,0,A61K47/30;;A61K9/14;;A61P25/28;;A61K31/765;;A61K31/795;;A61K47/30;;A61K9/14;;A61P25/28;;A61K9/0019;;A61K9/51;;A61K31/765;;A61K31/795,A61K31/765;;A61K9/00;;A61K9/14;;A61K9/51;;A61K31/795;;A61K47/30;;A61P25/28,,52,50,041-572-277-793-877;;049-161-556-854-382;;018-341-951-827-038;;081-297-869-273-733;;060-375-693-808-739;;008-976-672-288-488;;078-095-158-303-939;;048-418-018-879-843;;026-501-702-320-498;;021-480-171-483-80X;;026-080-553-072-386;;054-716-316-649-635;;117-773-330-241-016;;054-941-682-226-481;;040-118-190-236-350;;018-026-116-357-247;;038-678-253-697-634;;031-472-968-068-032;;101-452-782-767-424;;026-441-096-336-331;;007-417-001-564-86X;;010-571-719-659-992;;098-374-665-602-164;;033-834-296-851-902;;064-400-365-392-508;;082-405-046-309-258;;036-588-706-788-933;;056-364-022-781-231;;009-017-663-250-720;;039-474-172-356-004;;101-264-658-320-256;;018-054-995-043-559;;035-711-439-338-747;;074-572-551-205-482;;038-415-706-844-39X;;023-917-558-988-29X;;127-461-571-161-164;;027-024-518-203-926;;059-820-202-402-580;;045-585-236-680-639;;096-420-725-243-899;;057-370-947-247-249;;088-366-337-225-926;;009-425-294-524-37X;;058-987-485-267-742;;036-302-547-403-517;;128-121-226-620-02X;;022-532-246-722-616;;106-082-161-650-211;;033-350-450-718-480,10.1016/s0196-0644(05)82744-1;;8503521;;17018310;;10.1016/j.crad.2006.06.011;;10.1089/ars.2009.2668;;19624272;;10739643;;10.1006/exnr.1999.7338;;25918580;;pmc4397034;;10.1155/2015/370312;;10.1021/nn102845t;;22017172;;8751635;;10.3171/jns.1996.85.3.0476;;10.1038/mt.2015.22;;25669432;;pmc4427876;;10.1021/nn302615f;;22866916;;pmc3458163;;26079716;;10.3109/1061186x.2015.1034280;;10.1021/cr9001403;;19764725;;pmc4061598;;24994996;;10.3389/fneur.2014.00100;;22242774;;10.1021/ar200242z;;pmc3516364;;10.3410/f.7980956.8351056;;10.1016/s1474-4422(10)70300-8;;pmc3628679;;21169065;;10.1371/journal.pone.0061819;;pmc3634829;;23637912;;10.1089/ars.2012.4981;;23547621;;26708021;;10.1016/j.jconrel.2015.12.029;;10.1186/s12989-015-0108-2;;26525058;;pmc4630844;;10.1016/j.nurt.2009.10.021;;20129497;;pmc2818465;;10.1021/nn403743b;;24266731;;pmc4252540;;10.1523/jneurosci.3020-14.2014;;25471560;;20393189;;10.1126/scitranslmed.3000330;;pmc4636982;;25947369;;10.1007/s11064-015-1581-6;;pmc4449023;;26024446;;10.1371/journal.pone.0127971;;pmc3397249;;10.1002/adma.201102313;;21842473;;pmc4470501;;26097514;;10.1039/c4py01250j;;16983222;;10.1097/00001199-200609000-00001;;pmc4146500;;10.1002/adhm.201200423;;25136729;;10.1089/neu.2000.17.871;;11063054;;10.1227/neu.0b013e31820c02d9;;21273921;;10.2165/11634020-000000000-00000;;22668124;;10.1155/2013/379206;;pmc3654699;;23710445;;10.1071/ch12295;;10.7150/thno.8698;;pmc3982135;;24723986;;16257340;;10.1016/s0140-6736(05)67626-x;;19124559;;10.1096/fj.08-116947;;18509606;;pmc2670226;;10.1007/s12010-008-8232-1;;10.2174/0929867321666131217153310;;24350853;;9271001;;10.1007/bf02815156;;pmc3930079;;24317693;;10.1038/nature12808;;25221630;;pmc4159953;;10.1039/c3py01404e;;24201802;;10.1038/cddis.2013.362;;pmc3847304;;19413362;;10.1021/bm900325t;;pmc4667711;;26274493;;10.3109/02699052.2015.1065344;;10.1021/jf402242e;;23706102;;pmc3854945;;24241345;;10.1038/aps.2013.160;;10.1039/c4py01156b;;20691229;;10.1016/j.addr.2010.07.009;;pmc2988080;;10.1002/adfm.201504416;;8433137;;10.3171/jns.1993.78.3.0375,"Muizelaar, Cerebral ischemia-reperfusion injury after severe head injury and its possible treatment with polyethyleneglycol-superoxide dismutase, 1993, Annals of Emergency Medicine, vol. 22, Issue 6, pp. 1014-1021, Abstract only (3 pages). (Year: 1993).;;McKenna, Polyethylene glycol solution as an oral contrast agent for MRI of the small bowel in a patient population, 2006, Clinical Radiology, vol. 61, Issue 11, pp. 966-970, Abstract only (3 pages). (Year: 2006).;;Adibhatla, R.M., and J.F. Hatcher, “Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities,” Antioxidants & Redox Signaling 12(1):125-169, Jan. 2010.;;Albensi, B.C., et al., “Cyclosporin Ameliorates Traumatic Brain-Injury-Induced Alterations of Hippocampal Synaptic Plasticity,” Experimental Neurology 162(12):385-389, Dec. 2000.;;Angeloni, C., et al., “Traumatic Brain Injury and NADPH Oxidase: A Deep Relationship,” Oxidative Medicine and Cellular Longevity 2015:370312, 2015, pp. 1-10.;;Astete, C.E., et al., “Antioxidant Poly(lactic-co-glycolic) Acid Nanoparticles Made With R-Tocopherol Ascorbic Acid Surfactant,” ACS Nano 5(12):9313-9325, Dec. 2011.;;Baldwin, S.A., et al., “Blood-Brain Banier Breach Following Cortical Contusion in the Rat,” Journal of Neurosurgery 85(3):476-481, Sep. 1996.;;Berguig, G.Y., et al., “Intracellular Delivery System for Antibody-Peptide Drug Conjugates,” American Society of Gene & Cell Therapy 23(5):907-917, May 2015.;;Bitner, B.R., et al., “Antioxidant Carbon Particles Improve Cerebrovascular Dysfunction Following Traumatic Brain Injury,” ACS Nano 6(9):8007-8014, Sep. 2012.;;Boyd, B.J., et al., “Traumatic Brain Injury Opens Blood-Brain Barrier to Stealth Liposomes via an Enhanced Permeability and Retention (EPR)-Like Effect,” Journal of Drug Targeting 23(9):847-853, 2015.;;Boyer, C., et al., “Bioapplications of RAFT Polymerization,” Chemical Reviews 109(11):5402-5436, Nov. 2009.;;Chen, Y., et al., “A Modified Controlled Cortical Impact Technique to Model Mild Traumatic Brain Injury Mechanics in Mice,” Frontiers in Neurology 5:100, Jun. 2014, pp. 1-14.;;Chu, D.S.H., et al., “Application of Living Free Radical Polymerization for Nucleic Acid Delivery,” Accounts of Chemical Research 45(7):1089-1099, Jul. 2012.;;Clifton, G.L., et al., “Very Early Hypothermia Induction in Patients With Severe Brain Injury (the National Acute Brain Injury Study: Hypothermia II): A Randomised Trial,” The Lancet Neurology 10(2):131-139, Feb. 2011.;;Clond, M.A., et al., “Reactive Oxygen Species-Activated Nanoprodrug of Ibuprofen for Targeting Traumatic Brain Injury in Mice,” PLOS ONE 8(4):e61819, Apr. 2013, 10 pages.;;Cornelius, C., et al., “Traumatic Brain Injury: Oxidative Stress and Neuroprotection,” Antioxidants & Redox Signaling 19(8):836-853, Sep. 2013.;;Cruz, L.J., et al., “Effect of PLGA NP Size on Efficiency to Target Traumatic Brain Injury,” Journal of Controlled Release 223:31-41, Feb. 2016.;;Driessen, M.D., et al., “Proteomic Analysis of Protein Carbonylation: A Useful Tool to Unravel Nanoparticle Toxicity Mechanisms,” Particle and Fibre Toxicology 12:36, Dec. 2015, pp. 1-18.;;Frieden, T.R., et al., “Report to Congress: Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation,” submitted by Centers for Disease Control and Prevention, National Center for Injury Prevention and control, Atlanta, GA, 2015, 72 pages.;;Hall, E.D., et al., “Antioxidant Therapies for Traumatic Brain Injury,” Neurotherapeutics 7(1):51-61, Jan. 2010.;;Heckman, K.L., et al., “Custom Cerium Oxide Nanoparticles Protect Against a Free Radical Mediated Autoimmune Degenerative Disease in the Brain,” ACS Nano 7(12):10582-10596, Dec. 2013.;;Iliff, J.J., et al., “Impairment of Glymphatic Pathway Function Promotes Tau Pathology After Traumatic Brain Injury,” Journal of Neuroscience 34(49):16180-16193, Dec. 2014.;;Janowitz, T., and D.K. Menon, “Exploring New Routes for Neuroprotective Drug Development in Traumatic Brain Injury,” Science Translational Medicine 2(27):1-10, Apr. 2010.;;Jessen, N.A., et al., “The Glymphatic System: A Beginner's Guide,” Neurochemical Research 40(12):2583-2599, Dec. 2015.;;Kabu, S., et al., “Blast-Associated Shock Waves Result in Increased Brain Vascular Leakage and Elevated ROS Levels in a Rat Model of Traumatic Brain Injury,” PLOS ONE 10(5):e0127971, May 2015, 19 pages.;;Kievit, F.M., and M. Zhang, “Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers,” Advanced Healthcare Materials 23(36):H217-H247, 2011.;;Lane, D.D., et al., “Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents,” Polymeric Chemistry 6(8):1286-1299, Feb. 2015. (Author Manuscript provided, PMCID: PMC4470501, available in PMC Feb. 28, 2016, 31 pages.).;;Langlois, J.A., et al., “The Epidemiology and Impact of Traumatic Brain Injury,” Journal of Head Trauma Rehabilitation 21(5):375-378, 2006.;;Lee, S.H., et al., “Current Progress in Reactive Oxygen Species (ROS)-Responsive Materials for Biomedical Applications,” Adv Healthc Mat 2(6):908-915, 2013. (Author Manuscript provided, PMCID: PMC4146500, available in PMC Aug. 27, 2014, 15 pages.).;;Lewén, A., et al., “Free Radical Pathways in CNS Injury,” Journal of Neurotrauma 17(10):871-890, Oct. 2000.;;Marushima, A., et al., “Newly Synthesized Radical-Containing Nanoparticles Enhance Neuroprotection After Cerebral Ischemia-Reperfusion Injury,” Neurosurgery 68(5):1418-1426, May 2011.;;McConeghy, K.W., et al., “A Review of Neuroprotection Pharmacology and Therapies in Patients With Acute Traumatic Brain Injury,” CNS Drugs 26(7):613-636, Jul. 2012.;;Miyamoto, K., et al., “Therapeutic Time Window for Edaravone Treatment of Traumatic Brain Injury in Mice,” BioMed Research International 2013:379206, 2013, pp. 1-13.;;Moad, G., et al., “Living Radical Polymerization by the RAFT Process—A Third Update,” Australian Journal of Chemistry 65(8):985-1076, Sep. 2012.;;Muthu, M.S., et al., “Nanotheranostics—Application and Further Development of Nanomedicine Strategies for Advanced Theranostics,” Theranostics 4(6):660-677, Mar. 2014.;;Patel, H.C., et al., “Trends in Head Injury Outcome From 1989 to 2003 and the Effect of Neurosurgical Care: An Observational Study,” The Lancet 366(9496):1538-1544, Oct.-Nov. 2005.;;Reddy, M.K., and V. Labhasetwar, “Nanoparticle-Mediated Delivery of Superoxide Dismutase to the Brain: An Effective Strategy to Reduce Ischemia-Reperfusion Injury,” FASEB Journal 23(5):1384-1395, May 2009.;;Reddy, M.K., et al., “Superoxide Dismutase-Loaded PLGA Nanoparticles Protect Cultured Human Neurons Under Oxidative Stress,” Applied Biochemistry and Biotechnology 151:565-577, Dec. 2008.;;Rodríguez-Rodríguez, A., et al., “Oxidative Stress in Traumatic Brain Injury,” Current Medicinal Chemistry 21(10):1201-1211, Apr. 2014.;;Roof, R.L., et al., “Progesterone Protects Against Lipid Peroxidation Following Traumatic Brain Injury in Rats,” Molecular and Chemical Neuropathology 31(1):1-11, May 1997.;;Roth, T.L., et al., “Transcranial Amelioration of Inflammation and Cell Death After Brain Injury,” Nature 505(7482):223-228, Jan. 2014.;;Roy, D., et al., “Synthesis and Characterization of Transferrin-Targeted Chemotherapeutic Delivery Systems Prepared via RAFT Copolymerization of High Molecular Weight PEG Macromonomers,” Polymeric Chemistry 5(5):1791-1799, Mar. 2014. (Author Manuscript provided, PMCID: PMC4159953, available in PMC Mar. 7, 2015, 21 pages.).;;Singhal, A., et al., “Nanoparticle-Mediated Catalase Delivery Protects Human Neurons From Oxidative Stress,” Cell Death and Disease 4:e903, 2013, 9 pages.;;Spizzirri, U.G., et al., “Synthesis of Antioxidant Polymers by Grafting of Gallic Acid and Catechin on Gelatin,” Biomacromolecules 10(7):1923-1930, Jul. 2009.;;Stein, D.G., “Embracing Failure: What the Phase III Progesterone Studies Can Teach About TBI Clinical Trials,” Brain Injury 29(11):1259-1272, 2015.;;Wan, A., et al., “Antioxidant Activity of High Molecular Weight Chitosan and N,O-Quatemized Chitosans,” Journal of Agricultural and Food Chemistry 61(28):6921-6928, Jul. 2013.;;Wei, J., and G.-M. Xiao, “The Neuroprotective Effects of Progesterone on Traumatic Brain Injury: Current Status and Future Prospects,” Acta Pharmacologica Sinica 34(12):1485-1490, Dec. 2013.;;Xiao, C., et al., “Synthesis of Thermal and Oxidation Dual Responsive Polymers for Reactive Oxygen Species (ROS)-Triggered Drug Release,” Polymer Chemistry 6(5):738-747, Feb. 2015.;;Xie, J., et al., “Nanoparticle-Based Theranostic Agents,” Advanced Drug Delivery Reviews 62(11):1064-1079, Aug. 2010.;;Xu, J., et al., “Theranostic Oxygen Reactive Polymers for Treatment of Traumatic Brain Injury,” Advanced Functional Materials 26(23):4124-4133, 2016.;;International Search Report and Written Opinion dated Mar. 10, 2017, issued in corresponding International Application No. PCT/US2016/055809, filed Oct. 6, 2016, 11 pages.;;Muizelaar, J.P., et al., “Improving the Outcome of Severe Head Injury With the Oxygen Radical Scavenger Polyethylene Glycol-Conjugated Superoxide Dismutase: A Phase II Trial,” Journal of Neurosurgery 78(3):375-382, Mar. 1993.",ACTIVE
11,WO,A1,WO 2017/062657 A1,177-464-848-737-347,2017-04-13,2017,US 2016/0055809 W,2016-10-06,US 201562237915 P,2015-10-06,OXYGEN REACTIVE POLYMERS FOR TREATMENT OF TRAUMATIC BRAIN INJURY,"Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.",UNIV OF WAHSINGTON,XU JULIA MENGYUN;;YPMA MENKO R;;CHIARELLI PETER A;;PARK JOSHUA SANG HUN;;ELLENBOGEN RICHARD G;;STAYTON PATRICK S;;MOURAD PIERRE D;;LEE DONGHOON;;CONVERTINE ANTHONY;;KIEVIT FORREST M,,https://lens.org/177-464-848-737-347,Patent Application,yes,4,3,4,4,0,A61K47/30;;A61K9/14;;A61P25/28;;A61K31/765;;A61K31/795;;A61K47/30;;A61K9/14;;A61P25/28;;A61K9/0019;;A61K9/51;;A61K31/765;;A61K31/795,A61P25/00;;A61K47/30;;C07K14/805,,1,1,033-350-450-718-480,8433137;;10.3171/jns.1993.78.3.0375,"MUIZELAAR ET AL.: ""Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycolconjugated superoxide dismutase: a Phase II trial."", JOURNAL OF NEUROSURGERY, vol. 78, no. 3, 1993, pages 375 - 382, Retrieved from the Internet <URL:http://thejns.org/doi/abs/10,3171/jnepsilon.1993.78.3.0375?url_ver=Z39.88-2003&rfr_id-ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&> [retrieved on 20012017]",PENDING
12,US,A1,US 2022/0152091 A1,086-763-757-257-728,2022-05-19,2022,US 202117379401 A,2021-07-19,US 202117379401 A;;US 201815766314 A;;US 2016/0055809 W;;US 201562237915 P,2015-10-06,OXYGEN REACTIVE POLYMERS FOR TREATMENT OF TRAUMATIC BRAIN INJURY,"Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.",UNIV WASHINGTON,STAYTON PATRICK S;;YPMA MENKO P;;CHIARELLI PETER A;;PARK JOSHUA SANG HUN;;ELLENBOGEN RICHARD G;;XU JULIA MENGYUN;;MOURAD PIERRE D;;LEE DONGHOON;;CONVERTINE ANTHONY;;KIEVIT FORREST M,,https://lens.org/086-763-757-257-728,Patent Application,yes,0,0,4,4,0,A61K47/30;;A61K9/14;;A61P25/28;;A61K31/765;;A61K31/795;;A61K47/30;;A61K9/14;;A61P25/28;;A61K9/0019;;A61K9/51;;A61K31/765;;A61K31/795,A61K31/765;;A61K9/00;;A61K9/14;;A61K9/51;;A61K31/795;;A61K47/30;;A61P25/28,,0,0,,,,PENDING
